Greenwich, Connecticut, October 11, 2022 – Ceruvia Lifesciences, a leading neurotransformational medicine biopharmaceutical company, is pleased to announce that Yale professor, Dr. Christopher Pittenger, its Principle Investigator for the upcoming phase 2a trial of psilocybin for obsessive-compulsive disorder (OCD) and Yale assistant professor, Dr. Emmanuelle Schindler, a research collaborator investigating psilocybin for headache disorders, will present at Horizons New York psychedelic research forum on Friday, October 14 at 2:45pm Eastern Time. During their session, Emerging indications for psychedelic therapies, Dr. Pittenger will discuss early experience with the use of psilocybin to treat OCD, while Dr. Schindler will discuss the history and study of psychedelics in treating headache disorders.
For further details or to register to attend, please visit: https://www.horizonspbc.com/newyork
Discounted tickets to attend in-person may be purchased using the code:
About Ceruvia Lifesciences
Founded in 2017, Ceruvia Lifesciences is a clinical-stage biopharmaceutical company with a mission to improve the lives of underserved patients suffering from neurological and psychiatric disorders. Founded by Carey Turnbull, Ceruvia is relentlessly focused on the development and commercialization of neurotransformational medicines to deliver meaningful relief to patients suffering from hard-to-treat headache disorders, OCD and substance abuse disorder. For too long, these communities have been poorly understood and under-served. At Ceruvia, we believe they no longer have to live this way. Based on a long history of partnership with leading researchers at Yale University School of Medicine, NYU School of Medicine and Harvard Medical School, Ceruvia is undertaking clinical research in order to help them return to living their lives to the fullest. For more information, please visit www.ceruvialifesciences.com
Contact: Christopher Koddermann
Tel.: +41 (79) 434 25 78